Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

pembrolizumab 606Cyclophosphamide 546Magnetic Resonance Spectroscopy 527Radiotherapy 514Specimen Handling 506Nivolumab 412Cisplatin 381Carboplatin 369Biopsy 306Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 270Standard of Care 267Drug Therapy 264fludarabine 263Dexamethasone 263Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 199Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 185Doxorubicin 179Etoposide 177atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oxidoreductases × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡